Cytomegalovirus infection after liver transplantation: viral load as a guide to treating clinical infection.
BACKGROUND
Quantitative commercial assays for early and accurate detection of active cytomegalovirus (CMV) infection after liver transplantation are widely available. However, meaningful interpretation of viral load measurements is hampered by the lack of definitive cutoff points that correlate with clinically significant disease.


METHODS
One hundred fifty liver allograft recipients were prospectively monitored for the presence of CMV DNA for the first 12 weeks after orthotopic liver transplantation using the Murex hybrid capture system. The first CMV DNA value after liver transplantation, a weekly rise in CMV DNA (gradient value), and the CMV DNA value on clinical detection of active infection (critical value) were analyzed as risk factors for CMV infection.


RESULTS
Forty-four (29.3%) of 150 patients had detectable CMV DNA within 12 weeks of transplantation, and 20 (13.3%) experienced symptomatic CMV infection. Multiple regression analysis demonstrated that baseline CMV DNA level above 10 pg/mL, positive weekly increase in CMV DNA level, and critical CMV DNA level above 13 pg/mL were independent risk factors for clinically significant infection. Using Cox's multiple regression model, the hazard ratio was 13.9 for baseline CMV DNA above 10 (P =0.0001; 95% confidence interval, 3.5-54) and 13 for a weekly increase in the gradient (P =0.0003; 95% confidence interval, 3.5-50). Critical CMV DNA level above 13 correlated with active infection (100% sensitivity, 98% specificity, 90% positive predictive value, 100% negative predictive value).


CONCLUSIONS
Baseline and gradient CMV DNA viral load levels correlate with active CMV infection in liver allograft recipients. These data indicate that CMV viral load detection by hybridization methodology is useful in predicting active CMV infection and could be used in a preemptive strategy in liver allograft recipients.
D000328:Adult; D000914:Antibodies, Viral / Q000097:blood; D003586:Cytomegalovirus Infections / Q000175:diagnosis* / Q000188:drug therapy / Q000517:prevention & control; D004279:DNA, Viral / Q000097:blood*; D006801:Humans; D016031:Liver Transplantation / Q000009:adverse effects*; D016015:Logistic Models; D012680:Sensitivity and Specificity; D019562:Viral Load
D000914:Antibodies, Viral; D004279:DNA, Viral